Compare AstraZeneca plc (AZN) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Strategy Inc. — how do they compare? AstraZeneca plc trades at $169.06 (market cap $253.13B), while Strategy Inc. trades at $97.86 (market cap $35.38B). The key difference: AstraZeneca plc is far larger — about 7.2× Strategy Inc.'s market cap, and AstraZeneca plc pays a 1.92% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals.
| AZN | MSTR | |
|---|---|---|
Market Cap | $253.13B | $35.38B |
Sector | Health | Technology |
52-Week High | $209.48 | $455.90 |
52-Week Low | $137.44 | $82.31 |
Enterprise Value | $279.37B | $50.42B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
MSTR trades at $92.10, down 2.68% on the day, reflecting bearish technical signals and volatile earnings. The stock shows a low P/E of 5.3 and P/B of 0.91, but negative profitability metrics like a net income margin of -2,482.01% highlight financial strain. Recent news indicates scrutiny over Bitcoin-related strategy shifts, with cash flow heavily influenced by financing activities.
Outlook remains cautious due to persistent losses and high debt, though analyst consensus is bullish with a $237.63 price target. Key risks include earnings volatility and reliance on financing; investors should weigh valuation against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
